LifeVantage Corporation announced it has completed an international study of its MindBody GLP-1 System. The in vitro cell study used Enzyme-Linked Immunosorbent Assay (ELISA) to measure total GLP-1 production and used fluorescent microscopy to visualize outcomes.
Details from the study, which focused on identifying the synergistic potential of the active blends from the two-product system, will be revealed at the company’s Global Convention in April.
“The completion of this trial and the positive results we’re starting to see with this international formula affirm our success in activating the body’s own production of the GLP-1 hormone,” said Lisa Barnes, LifeVantage VP of R&D and Regulatory. “We’re excited to bring the MB System to our international audience starting in March and provide them with the same life-changing results that have already transformed the health of so many.”
